With 0.71 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.37 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.61 whereas the lowest price it dropped to was $2.19. The 52-week range on RDHL shows that it touched its highest point at $9.05 and its lowest point at $1.06 during that stretch. It currently has a 1-year price target of $1000.00. Beta for the stock currently stands at 4.56.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was up-trending over the past week, with a rise of 50.90%, but this was up by 93.85% over a month. Three-month performance surged to 26.00% while six-month performance fell -1.18%. The stock lost -59.42% in the past year, while it has lost -70.80% so far this year.
Float and Shares Shorts:
At present, 3.33 million RDHL shares are outstanding with a float of 3.31 million shares on hand for trading. On 2025-09-15, short shares totaled 37835.0, which was 114.00000000000001 higher than short shares on 1755216000. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, Chairman & CEO, Mr. Razi Ingber serves as its Chief Financial Officer.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$40 being high and -$40 being low. For RDHL, this leads to a yearly average estimate of -$40. The surprise factor in the prior quarter was -$10.
